Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California. more
Time Frame | BBIO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.52% | -2.27% | -0.57% |
1-Month Return | 10.89% | -3.96% | 1.21% |
3-Month Return | 5% | -9.7% | 7.57% |
6-Month Return | -5.21% | -3.37% | 11.45% |
1-Year Return | -21.9% | 3.71% | 28.48% |
3-Year Return | -27.71% | 3.8% | 29.52% |
5-Year Return | -24.68% | 39.78% | 90.66% |
10-Year Return | -0.22% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 40.56M | 8.25M | 69.72M | 77.65M | 9.30M | [{"date":"2019-12-31","value":52.24,"profit":true},{"date":"2020-12-31","value":10.62,"profit":true},{"date":"2021-12-31","value":89.78,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":11.98,"profit":true}] |
Cost of Revenue | 2.50M | 3.09M | 3.11M | 3.43M | 2.45M | [{"date":"2019-12-31","value":72.8,"profit":true},{"date":"2020-12-31","value":89.92,"profit":true},{"date":"2021-12-31","value":90.68,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":71.23,"profit":true}] |
Gross Profit | 38.06M | 5.16M | 66.60M | 74.21M | 6.86M | [{"date":"2019-12-31","value":51.28,"profit":true},{"date":"2020-12-31","value":6.95,"profit":true},{"date":"2021-12-31","value":89.74,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":9.24,"profit":true}] |
Gross Margin | 93.84% | 62.57% | 95.53% | 95.58% | 73.71% | [{"date":"2019-12-31","value":98.18,"profit":true},{"date":"2020-12-31","value":65.46,"profit":true},{"date":"2021-12-31","value":99.95,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":77.12,"profit":true}] |
Operating Expenses | 304.30M | 482.73M | 646.35M | 546.09M | 614.23M | [{"date":"2019-12-31","value":47.08,"profit":true},{"date":"2020-12-31","value":74.69,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.49,"profit":true},{"date":"2023-12-31","value":95.03,"profit":true}] |
Operating Income | (266.24M) | (474.48M) | (579.75M) | (471.87M) | (607.37M) | [{"date":"2019-12-31","value":-26624000000,"profit":false},{"date":"2020-12-31","value":-47448200000,"profit":false},{"date":"2021-12-31","value":-57974600000,"profit":false},{"date":"2022-12-31","value":-47187100000,"profit":false},{"date":"2023-12-31","value":-60737000000,"profit":false}] |
Total Non-Operating Income/Expense | (22.20M) | (63.65M) | (55.47M) | (45.35M) | (109.13M) | [{"date":"2019-12-31","value":-2219500000,"profit":false},{"date":"2020-12-31","value":-6364600000,"profit":false},{"date":"2021-12-31","value":-5546700000,"profit":false},{"date":"2022-12-31","value":-4534600000,"profit":false},{"date":"2023-12-31","value":-10913200000,"profit":false}] |
Pre-Tax Income | (288.58M) | (505.49M) | (586.45M) | (484.65M) | (653.25M) | [{"date":"2019-12-31","value":-28858500000,"profit":false},{"date":"2020-12-31","value":-50548800000,"profit":false},{"date":"2021-12-31","value":-58645400000,"profit":false},{"date":"2022-12-31","value":-48465200000,"profit":false},{"date":"2023-12-31","value":-65325100000,"profit":false}] |
Income Taxes | (28.15M) | (21.56M) | 52.84M | 9.31M | 71.51M | [{"date":"2019-12-31","value":-39.36,"profit":false},{"date":"2020-12-31","value":-30.15,"profit":false},{"date":"2021-12-31","value":73.9,"profit":true},{"date":"2022-12-31","value":13.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (260.44M) | (483.93M) | (639.30M) | (493.96M) | (724.76M) | [{"date":"2019-12-31","value":-26043700000,"profit":false},{"date":"2020-12-31","value":-48392500000,"profit":false},{"date":"2021-12-31","value":-63929700000,"profit":false},{"date":"2022-12-31","value":-49396400000,"profit":false},{"date":"2023-12-31","value":-72476100000,"profit":false}] |
Income From Continuous Operations | (288.58M) | (505.49M) | (586.45M) | (484.65M) | (653.25M) | [{"date":"2019-12-31","value":-28858500000,"profit":false},{"date":"2020-12-31","value":-50548800000,"profit":false},{"date":"2021-12-31","value":-58645400000,"profit":false},{"date":"2022-12-31","value":-48465200000,"profit":false},{"date":"2023-12-31","value":-65325100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (260.44M) | (483.93M) | (639.30M) | (493.96M) | (643.20M) | [{"date":"2019-12-31","value":-26043700000,"profit":false},{"date":"2020-12-31","value":-48392500000,"profit":false},{"date":"2021-12-31","value":-63929700000,"profit":false},{"date":"2022-12-31","value":-49396400000,"profit":false},{"date":"2023-12-31","value":-64320200000,"profit":false}] |
EPS (Diluted) | (7.84) | (3.80) | (3.91) | (3.11) | (3.94) | [{"date":"2019-12-31","value":-784,"profit":false},{"date":"2020-12-31","value":-380,"profit":false},{"date":"2021-12-31","value":-391,"profit":false},{"date":"2022-12-31","value":-311,"profit":false},{"date":"2023-12-31","value":-394,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BBIO | |
---|---|
Cash Ratio | 1.91 |
Current Ratio | 3.19 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BBIO | |
---|---|
ROA (LTM) | -48.88% |
ROE (LTM) | -1789.67% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BBIO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 2.83 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -1.85 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BBIO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 25.15 |
P/B | 123.68 |
Price/FCF | NM |
EV/R | 30.58 |
EV/Ebitda | NM |
BridgeBio Pharma Inc (BBIO) share price today is $27.49
Yes, Indians can buy shares of BridgeBio Pharma Inc (BBIO) on Vested. To buy BridgeBio Pharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BBIO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of BridgeBio Pharma Inc (BBIO) via the Vested app. You can start investing in BridgeBio Pharma Inc (BBIO) with a minimum investment of $1.
You can invest in shares of BridgeBio Pharma Inc (BBIO) via Vested in three simple steps:
The 52-week high price of BridgeBio Pharma Inc (BBIO) is $44.32. The 52-week low price of BridgeBio Pharma Inc (BBIO) is $21.62.
The price-to-earnings (P/E) ratio of BridgeBio Pharma Inc (BBIO) is
The price-to-book (P/B) ratio of BridgeBio Pharma Inc (BBIO) is 123.68
The dividend yield of BridgeBio Pharma Inc (BBIO) is 0.00%
The market capitalization of BridgeBio Pharma Inc (BBIO) is $5.48B
The stock symbol (or ticker) of BridgeBio Pharma Inc is BBIO